Management of the PDA Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 482 participants.

Also called NCT03456336

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 482 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03456336
Other papers using this trial's data
  • Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial JAMA, 2026-02-17 DOI, PubMed 41364689, PMC12690482 PubMed links an erratum for this paper. Erratum: PMID 41854607 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03456336. Randomized; no masking; primary purpose treatment. Start 2019-02-22 (actual); primary completion 2025-03-02 (actual). Results posted on 2026-05-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Management of the PDA Trial
Acronym
PDA
Condition
Infant, Premature
Condition
Patent Ductus Arteriosus
Condition
Infant, Newborn, Diseases
Condition
Patent Ductus Arteriosus After Premature Birth
Intervention (Other)
Active Treatment
Intervention (Other)
Expectant Management
Lead sponsor
NICHD Neonatal Research Network (class: research network)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03456336
Content hash
9550a632f0569efb0d2ea6e41aed055484ac9855e772fd206b458b65b02b57b0